Table 3.

Association of UA^*, UA/Cr ratio^* with COVID-19 and gender

		Model 1	Model 2	Model 3
		β (95% CI)	β (95% CI)	β (95% CI)
UA#	COVID-19	−0.25† (− 0. 20, − 0.10)	−0.21† (− 0.20, − 0.06)	−0.15† (− 0.17, − 0.01)
	Male	0.50† (0.22, 0.31)	0.53† (0.22, 0.33)	0.47† (0.19, 0.30)
	COVID-19*Male	–	−0.06 (− 0.15, 0.06)	−0.001 (− 0.10, 0.10)
	AIC	−79.27	−78.03	− 111.46
	BIC	−63.68	−58.54	− 72.49
UA/Cr ratio#	COVID-19	−0.21† (− 0.16, − 0.06)	−0.13 (− 0.13, 0.01)	−0.06 (− 0.11, 0.05)
	Male	−0.12† (− 0.10, − 0.01)	−0.07 (− 0.09, 0.02)	−0.08 (− 0.09, − 0.02)
	COVID-19*Male	–	−0.13 (− 0.20, − 0.01)	−0.11 (− 0.18, 0.02)
	AIC	−68.02	−69.28	−83.80
	BIC	− 52.43	−49.80	−48.72

Note: Linear regression analysis was used to assess association of UA*, UA/Cr ratio* with COVID-19 and gender

Abbreviations: AIC Akaike information criterion, BIC Bayesian Information Criterions

Model 1: Including COVID-19 and gender

Model 2: Including Model 1 and COVID-19*gender

Model 3 of UA^#: Including Model 2 and LEU^#†, LYM%^†, eGFR^#†, ALB/GLB, FPG^†

Model 3 of UA/Cr ratio^#: Including Model 2 and LEU^#†, LYM%^†, ALB/GLB, FPG

The P-values are for the beta coefficient

a^#: The data were transformed into Ln (a)

^†P <0.05